Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia

Blood blood.2025030722.

https://doi.org/10.1182/blood.2025030722

Published: 2026

Includes: Supplemental data

Journal Articles

Multivariable-adjusted validation of IWG23-defined peripheral blood complete remission (PB-CR) and IWG23 response criteria in 2,042 patients with MDS, CMML or AML treated with diverse first-line therapies: Insights from the AML-001 trial (NCT01074047) and the ‘austrian myeloid registry’ (NCT04438889) of the AGMT study group

Blood (2025) 146 (Supplement 1): 3859.

https://doi.org/10.1182/blood-2025-3859

Published: 2025

Journal Articles

Time-dependent long short-term memory neural cox regression in 2,690 patients with myeloid neoplasias treated with diverse therapies identifies bone marrow related information to be less important than expected in the context of other available clinical parameters: Insights from the AML-001 trial (NCT01074047) and the austrian myeloid registry (NCT04438889) of the AGMT study group

Blood (2025) 146 (Supplement 1): 48.

https://doi.org/10.1182/blood-2025-48

Published: 2025

Journal Articles

Validation of Recent Response Criteria (ELN-22, IWG-23 and PB-CR) in 1634 MDS/CMML/AML Patients Treated with HMA or HMA-Ven Using CPH Models and a CPH Deep Neural Network - Can or Should Response Criteria be Harmonized for Similarly Treated Patients?

Blood (2024) 144 (Supplement 1): 7511.

https://doi.org/10.1182/blood-2024-208073

Published: 2024

Journal Articles

Real-World Comparison of Outcomes of Patients Treated with HMA Monotherapy Versus HMA-Ven - Insights from 1634 Patients Included within the Austrian Myeloid Registry of the AGMT Study Group

Blood (2024) 144 (Supplement 1): 3793.

https://doi.org/10.1182/blood-2024-207230

Published: 2024

Journal Articles

Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup Napoleon Registry

Uwe Platzbecker, MD, Eva Lengfelder, MD, Kerstin Schäfer-Eckart, MD, Katharina S Götze, MD, Michael Heuser, MD, Felicitas Thol, MD, Helmut R. Salih, MD, Mathias Hänel, MD, Karsten Spiekermann, Sonja Martin, MD, Sigrid Machherndl-Spandl, MD, Volker Kunzmann, MD, Andreas Jakob, MD, Hans-Joachim Tischler, MD, Dirk Niemann, MD, Joerg Mezger, MD, Tilmann Bochtler, MD, Stefan Krause, MD, Maike de Wit, MD, Claudia D. Baldus, MD, Richard Greil, MD, Jochen Greiner, Mark Ringhoffer, MD, Markus Radsak, MD, Mohammed Amen Wattad, MD, Wolff Schmiegel, MD, Elisabeth Koller, MD, Frank Heits, MD, Albrecht Reichle, MD, Stephan Kremers, MD, Andreas Hochhaus, MD, Nadezda Basara, MD, Dominik Wolf, MD, Martin Goerner, MD, Markus Schaich, MD, Harald Biersack, MD, Heinz Kirchen, MD, Thomas Kubin, MD, Gregor Aschauer, MD, Tanja Hesse, MD, Hartmut Link, MD PhD, Heinz Duerk, MDPhD, Dorit Kuerschner, MD, Walter Fiedler, MD, Bernd Hertenstein, MD, Martin Puttrich, Michael Kramer, M.Sc., Michaela Sauer, Wolfgang Hiddemann, Ulrich Duehrsen, MD, Hubert Serve, Christian Thiede, MD, Arnold Ganser, MD, Tim H. Brummendorf, MD, Konstanze Dohner, MD, Martin Bornhäuser, MD, Richard F. Schlenk, MD, Christoph Rollig, MD MSC, Hartmut Döhner, MD, Gerhard Ehninger, Peter Paschka, MD

Blood (2017) 130 (Supplement 1): 2618.

https://doi.org/10.1182/blood.V130.Suppl_1.2618.2618

Published: 2017

Journal Articles

Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup Napoleon Registry

Uwe Platzbecker, MD, Eva Lengfelder, MD, Katharina S Goetze, MD, Christoph Röllig, MD, Michael Kramer, Michaela Sauer, Nadine Albers, Michael Heuser, Hartmut Link, MD PhD, Kerstin Schäfer-Eckart, MD, Sonja Martin, MD, Stefan W. Krause, MD, Mathias Hänel, MD, Tilmann Bochtler, MD, Andreas Jakob, MD, Albrecht Reichle, MD, Harald Biersack, MD, Claudia D. Baldus, MD, Martin Goerner, MD, Nadezda Basara, MD, Joerg Mezger, MD, Ralph Naumann, MD, Dorit Kuerschner, MD, Maike de Wit, Florian Nolte, MD, Mark Ringhoffer, MD, Hans-Joachim Tischler, MD, Jochen Greiner, Stephan Kremers, Sigrid Machherndl-Spandl, MD, Elisabeth Koller, MD, Mohammad Amen Wattad, MD, Gregor Aschauer, MD, Markus Radsak, MD, Thomas Kubin, MD, Helmut Salih, MD, Frank Heits, MD, Dominik Wolf, MD, Christian Thiede, MD, Hubert Serve, MD, Ulrich Duehrsen, MD, Andreas Hochhaus, MD, Tim H. Brümmendorf, MD, Martin Bornhäuser, MD, Hartmut Döhner, MD, Gerhard Ehninger, MD, Richard F. Schlenk, MD

Blood (2016) 128 (22): 2815.

https://doi.org/10.1182/blood.V128.22.2815.2815

Published: 2016

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia

Validation of Recent Response Criteria (ELN-22, IWG-23 and PB-CR) in 1634 MDS/CMML/AML Patients Treated with HMA or HMA-Ven Using CPH Models and a CPH Deep Neural Network - Can or Should Response Criteria be Harmonized for Similarly Treated Patients?

Real-World Comparison of Outcomes of Patients Treated with HMA Monotherapy Versus HMA-Ven - Insights from 1634 Patients Included within the Austrian Myeloid Registry of the AGMT Study Group

Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup Napoleon Registry

Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup Napoleon Registry

Email alerts

ASH Publications

American Society of Hematology

Update search

Phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia

Validation of Recent Response Criteria (ELN-22, IWG-23 and PB-CR) in 1634 MDS/CMML/AML Patients Treated with HMA or HMA-Ven Using CPH Models and a CPH Deep Neural Network - Can or Should Response Criteria be Harmonized for Similarly Treated Patients?

Real-World Comparison of Outcomes of Patients Treated with HMA Monotherapy Versus HMA-Ven - Insights from 1634 Patients Included within the Austrian Myeloid Registry of the AGMT Study Group

Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup Napoleon Registry

Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup Napoleon Registry

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only